TY - JOUR AU - Sruamsiri, Rosarin AU - Chaiyakunapruk, Nathorn AU - Pakakasama, Samart AU - Sirireung, Somtawin AU - Sripaiboonkij, Nintita AU - Bunworasate, Udomsak AU - Hongeng, Suradej PY - 2013 DA - 2013/02/05 TI - Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program JO - BMC Health Services Research SP - 45 VL - 13 IS - 1 AB - Hematopoieticic stem cell transplantation is the only therapeutic option that can cure thalassemia disease. Reduced intensity hematopoietic stem cell transplantation (RI-HSCT) has demonstrated a high cure rate with minimal complications compared to other options. Because RI-HSCT is very costly, economic justification for its value is needed. This study aimed to estimate the cost-utility of RI-HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for adolescent and young adult with severe thalassemia in Thailand. SN - 1472-6963 UR - https://doi.org/10.1186/1472-6963-13-45 DO - 10.1186/1472-6963-13-45 ID - Sruamsiri2013 ER -